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1ABSTRACT
The radio-sensitizing effect and tumor growth inhibition by 
cystine/glutamate transporter (system xc-) inhibition in glioblastoma
Hong In Yoon
Department of Medical Science
The Graduate School, Yonsei University
(Directed by Professor Chul Hoon Kim)
Glioblastoma is the most aggressive brain tumor. Despite existing 
multimodal therapy, new therapeutic strategies are required. System xc-, 
composed of a light-chain subunit (xCT, SLC7A11) and a heavy chain 
subunit (CD98hc, SLC3A2), releases glutamate outside the cell and 
concurrently uptakes cystine in the cell at a 1 to 1 ratio. The increased 
intracellular cystine, due to uptake by system xc-, is transformed into 
glutathione (GSH) that is one of the most important antioxidants in cancer 
cells, contributing to cancer cell survival and proliferation. So, I 
investigated that the inhibition of system xc- could improve the radio-
sensitivity and reduce the cell growth and migration in glioblastoma.
Herein, I show that system xc- inhibition could enhance radio-
sensitivity and repress glioblastoma progression and invasion. System xc-
inhibition induces a decrease in intracellular GSH in glioblastoma. 
2Irradiation combined with system xc- inhibition increases DNA double 
strand breaks (DSB) than that with irradiation alone in glioblastoma. The 
combination of irradiation and system xc- inhibition resulted in a 
significantly lower surviving fraction at each dose than irradiation alone.
Irradiation could induce the change of mesenchymal markers. 
Additionally, the expression of the Cancer Genome Atlas (TCGA)-based 
markers of mesenchymal glioblastoma, CD44 and YKL-40, was elevated 
after the irradiation. System xc- inhibition reduced cell migration through 
the change of mesenchymal markers in glioblastoma. Although irradiation 
significantly increased cell movement, system xc- inhibition blocked the 
radiation-induced cell migration. System xc- inhibition is significantly 
related to decrease in mesenchymal markers, including SNAIL, vimentin, 
N-cadherin, alpha-SMA and FAP in glioblastoma. System xc- protein 
expression was significantly higher in the mesenchymal than that in the 
proneural human glioblastoma specimens.
In conclusion, these findings demonstrate that system xc- inhibition 
in combination with irradiation could decrease cystine uptake and GSH, 
inducing an increase in DNA DSB. System xc- inhibition could enhance 
radio-sensitivity in glioblastoma. In addition, system xc- inhibition 
prevented the radiation-induced cell migration and affected mesenchymal 
features, which are adverse prognostic factors in glioblastoma. Taken 
together, my results indicate that the combination of radiation therapy (RT) 
and system xc- inhibition could improve therapeutic outcomes in 
glioblastoma.
Key words: System xc-, Cystine/glutamate transporter, Irradiation, 
Radio-sensitivity, Migration 
3The radio-sensitizing effect and tumor growth inhibition by 
cystine/glutamate transporter (system xc-) inhibition in glioblastoma
Hong In Yoon
Department of Medical Science
The Graduate School, Yonsei University
(Directed by Professor Chul Hoon Kim)
I. INTRODUCTION
Despite multimodal approaches for the treatment of glioblastoma, 
including radical resection followed by postoperative radiotherapy (RT) and 
temozolomide, new therapeutic strategies to enhance radio-sensitivity are needed 
and investigated due to poor prognosis and radio-resistance of glioblastoma. 
Ionizing radiation (IR) causes deoxyribonucleic acid (DNA) double strand 
breaks (DSB). The major mechanism of IR-induced DNA damage involves the 
indirect induction of reactive oxygen species (ROS), which is responsible for 70% 
of total IR-induced DNA DBS. This implies that enhancing indirect actions of IR 
could improve radio-sensitivity.
System xc-, a cystine/glutamate antiporter, releases glutamate outside the 
cell and concurrently uptakes cystine in the cell at a 1 to 1 ratio.1-5 Intracellular 
4cystine is then transformed into cysteine and finally glutathione (GSH), one of 
the most important antioxidants in mammalian cells as well as cancer cells, 
which protects cancer cells from intracellular ROS generated by external insults 
such as IR.6,7 In glioblastoma, the expression levels of system xc
- are higher than 
those in normal astrocytes. A retrospective study using surgical specimens from 
patients with glioblastoma demonstrated that the increase in system xc
-
expression level was significantly associated with poor prognosis.8 It was 
reported that when the function of system xc- is inhibited, intracellular GSH 
levels decreased, resulting in a decrease in tumor growth.9 Thus, studies 
investigating whether combining RT with a system xc- inhibitor could enhance 
the radio-sensitivity of glioblastoma and improve therapeutic effects are 
necessary. In addition, some studies demonstrated that malignant glioma can 
release glutamate by system xc-, inducing excitotoxicity in normal neurons and 
astrocytes and facilitating tumor progression.10,11
I hypothesized that system xc- inhibition could increase ROS effects and 
DNA damage after IR in glioblastoma by enhancing radio-sensitivity. In addition, 
I hypothesized that the inhibition of system xc- could repress glioblastoma
progression and invasion. So, I evaluated that system xc- would enhance the 
radio-sensitivity and reduce the cell growth and migration in glioblastoma.
1. Glioblastoma treatment and prognosis
Glioblastoma is the most common malignant brain tumor.12,13 This disease 
is the most aggressive brain tumor associated with poor survival despite 
combination therapy of radical resection followed by RT and temozolomide.14,15
5The standard treatment for newly diagnosed patients with glioblastoma is 
radical resection followed by postoperative RT combined with chemotherapy.16
RT is typically delivered as 60 Gy per 30 fractions to the patients’ postoperative 
tumor bed or residual tumors. Temozolomide, an oral DNA alkylating agent, is 
administered concurrently with radiotherapy and in an adjuvant setting after RT. 
In spite of aggressive treatment, glioblastoma of infiltrative features and radio-
resistance commonly result in disease progression.17-19 Thus, new therapeutic 
strategies to enhance radio-sensitivity are required.
2. Ionizing radiation, DNA damage, and radio-sensitivity
IR carries enough energy to free electrons to ionize atoms or molecules. IR 
includes a photon radiation such as γ-ray, X-ray, and the higher energy of 
ultraviolet part of the electromagnetic spectrum. 
DNA damage is an alteration in the chemical structure of DNA, including 
a break in one or both strands of DNA and a missing base from the DNA 
backbone. DNA damage can be induced by ROS, reactive nitrogen species, 
reactive carbonyl species, lipid peroxidation products, chemotherapy such as 
alkylating agents, and IR.20
IR causes DSB, the most deleterious type of DNA damage, which leads to 
cell death if DNA repair does not occur.21 The mechanism of DNA damage by 
IR consists of direct and indirect actions (Figure 1). Direct action occurs when 
particle radiation such as α, or β particles, neutron, proton or carbon ion break 
the sugar phosphate backbones or the base pairs of the DNA. In the indirect 
action, when IR such as photon radiation is absorbed in a biological material, 
ROS are produced. These ROS are highly reactive molecules. ROS could break 
6chemical bonds in DNA, produce chemical changes, and initiate the chain of 
events that results in biological damage. This represents the indirect effect of 
photon radiation on DNA, which constitutes 70% of total DNA DBS. This 
finding demonstrates that enhancing the indirect action of radiation could 
improve radio-sensitivity. 
Figure 1. Irradiation induces ROS production, which results in DNA DSB.
The mechanism of DNA damage by IR consists of direct and indirect actions by
x-ray.
73. System xc
-
A. System xc
- composition and function 
System xc
-, a cystine/glutamate antiporter, releases glutamate outside the 
cell and concurrently uptakes cystine in the cell at a 1 to 1 ratio (Figure 2).1-5
System xc- is one of the representative solute carriers and one of the 
representative amino acid transporters overexpressed in tumor cells.22 System xc-
is composed of a light-chain subunit (xCT, SLC7A11) and a heavy chain subunit 
(CD98hc, SLC3A2). xCT expression levels are known to correlate with system 
xc- activity, because xCT determines the substrate specificity and efficiency of 
system xc-. The increase of intracellular cystine by system xc- results in the 
production of cysteine and, finally, GSH, which is one of the most important 
antioxidants in mammalian cells.23
B. System xc- in cancer and resistance to cancer treatment 
Generally, cancer cells generate a substantial amount of ROS due to 
their enhanced metabolism and growth. Intracellular antioxidants play a critical 
role in preventing ROS damage. GSH is known to be representative of 
intracellular antioxidants and elevated in cancer cells. In addition, the elevated 
GSH in cancer cells could protect cancer cells from intracellular ROS generated 
by external insults such as IR.6,7,24 Thus, system xc- expression level increases in 
various types of cancer, because surface expression of system xc- is critical for 
the uptake of cystine required for intracellular GSH synthesis and the 
8maintenance of the redox balance.25 Therefore, modulation of the xCT activity of 
system xc
- has been considered as a new cancer therapeutic target.22
Several studies demonstrate that system xc
- contributes to cancer growth, 
invasion, progression, and metastasis in various types of cancer.25-28 In a study 
using an esophageal squamous cell cancer cell line, depletion of xCT using a 
drug inhibitor could inhibit cancer cell metastasis via the caveolin-1/b-catenin 
pathway.26 Some studies reported that the interaction between system xc
- and 
CD44, which is an adhesion molecule expressed in cancer stem-like cells, is 
important for tumor growth, progression, and resistance to cancer therapy.25,27,28
Ishimoto et al. demonstrated that a CD44 variant interacts with xCT and controls 
reduced GSH intracellular levels.25 A high level of CD44 expression is 
associated with an enhanced capacity for GSH synthesis and defense against 
ROS in gastro-intestinal cancer.25 Yoshikawa et al. showed that xCT inhibition 
selectively induces the apoptosis of CD44v-expressing tumor cells that are 
resistant to EGFR-targeted therapy in head and neck squamous cell carcinoma.28
Combination with xCT and EGFR inhibitors resulted in a synergistic reduction 
of EGFR-expressing tumor growth. Furthermore, system xc- induced radio-
resistance and chemo-resistance have been reported in several studies for various 
types of cancer.26,29-31
9Figure 2. System xc
- is a cystine/glutamate transporter. System xc- is 
composed of a light-chain subunit (xCT, SLC7A11) and a heavy chain subunit 
(CD98hc, SLC3A2). Through system xc-, cystine is transported into cells in 
exchange for the release of glutamate at a one to one ratio.
C. System xc- affects cell growth in glioblastoma
GSH is abundantly present in human brain tumors.32 Cystine necessary 
to produce GSH is also provided through system xc- in glioma. According to 
previous studies, the expression levels of system xc
- in glioblastoma are higher 
than those in normal astrocytes.9 It was reported that when system xc- function is 
inhibited, intracellular GSH levels as well as tumor growth decreased.9
A retrospective study using surgical specimens from patients 
demonstrated that the increase in system xc- expression levels was significantly 
associated with poor prognosis.8 In normal brain areas, weak xCT expression 
was observed in leptomeningeal cells and scattered astrocytes. Among 
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glioblastoma specimens from 40 patients, 50% of patients showed strong 
expression of xCT. On multivariate analysis, strong expression of xCT was an 
independent prognostic factor for progression-free survival and overall survival. 
Recently, a study reported the mechanism of ROS-mediated therapeutic 
resistance in glioblastoma.33 Microarray, Taqman, and functional assays used in 
this study demonstrated that therapeutic resistance was mediated by enhanced 
expression of the antioxidant response system xc
- catalytic subunit xCT. 
Thus, in glioblastoma, studies are required to determine whether the 
combination of RT with a system xc- inhibitor could enhance the radio-sensitivity 
and improve therapeutic effects. Inhibition of system xc- would also allow the use 
of lower doses of RT by enhancing radio-sensitivity, thereby reducing RT-
related toxicity and sequelae in the normal brain after RT for glioblastoma.
D. System xc- and cancer cell migration
The effect of system xc- in glioblastoma arises from cystine uptake as 
well as glutamate release. The extracellular glutamate released by system xc-
promotes glioma cell growth and destructs the adjacent normal tissue by 
inducing neuro-cytotoxicity and tumor expansion, facilitated by the activation of 
NMDA receptors.10,11,34-36 Thus, system xc
- inhibition does not only affect the 
redox status, but also inhibits tumor growth through the decrease of glutamate 
release, which plays a critical role in reducing the progression and invasion of 
glioblastoma. 
Several subtypes of glioblastoma, varying in molecular circuitry and 
biological behavior, have been identified. These include the proneural, neural, 
classical, and mesenchymal types.37,38 Interestingly, each subtype harbors distinct 
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genetic aberrations and proteomic profiles. Glioblastoma subtypes appear to 
differ in their clinical courses and therapeutic responses. Among them, the 
proneural type harbors frequent mutations in p53, platelet-derived growth factor 
receptor A, and isocitrate dehydrogenase (IDH) 1. In contrast, the mesenchymal 
type is characterized by frequent mutations in the neurofibromatosis type 1 gene 
(NF-1). The signature of mesenchymal glioblastoma is known as YKL-40 and 
CD44 positive. Patients presenting proneural glioblastoma survive longer than 
patients with mesenchymal glioblastoma.39
In 2007, a study reported that IR induces changes associated with 
epithelial-mesenchymal transition (EMT) and increases cell motility of lung 
cancer cells.40 Radiation induced an increase in g-H2AX expression and a 
decrease in E-cadherin expression. After 48 hours following radiation, cell 
migration increased in the radiation group when compared to the control group.41
In 2014, other study described that IR induces glial-mesenchymal transition 
similar to EMT and affects mesenchymal markers in malignant glioma (MG).42
In 22 cases presenting clinically recurrent MG, the expression of the 
mesenchymal marker vimentin increased. Among the regulators of mesenchymal 
transition, snail elevation was observed in MG cells at 2 days after irradiation. 
CD44, a mesenchymal marker of glioblastoma, is known to enhance the 
stabilization and function of xCT and to promote tumor growth.25
4. The purpose of this study
It is hypothesized that system xc- inhibition could increase ROS effects and 
DNA damage after IR in glioblastoma and xCT inhibition could prevent 
glioblastoma migration. The aim of my study is to investigate the enhanced 
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radio-sensitivity and reduced cell growth and migration by system xc
- inhibition 
in glioblastoma using glioblastoma cell-lines and human tissues.
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II. MATERIALS AND METHODS
1. Glioblastoma cell lines and culture
Glioma cells, U87-MG (human glioblastoma cell line, ATCC Number: 
HTB-14™, American Type Culture Collection, Manassas, VA, USA), and A172 
cells (human glioblastoma cell line, ATCC Number: CRL-1620™, American 
Type Culture Collection) were used in this study. U87-MG cells were cultured in 
Eagle's Minimum Essential Medium (EMEM) supplemented with 10% fetal 
bovine serum (FBS) and 1% penicillin-streptomycin. A172 cells were cultured in 
Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 10% FBS 
and 1% penicillin-streptomycin.
2. Cortical astrocytes
Cortical astrocytes were prepared from Sprague Dawley rats using a 
protocol described previously.43 All protocols were approved by the Institutional 
Animal Care and Use Committee of Yonsei University Health System. The 
cortices, which were removed from early postnatal mice (postnatal days 1–3), 
were used, while the hippocampal formation, basal ganglia, and most of the 
meninges were discarded. Thereafter, the tissue was minced and incubated in 
0.08% acetylated trypsin for 45–75 minutes at 37°C. The tissue was then 
dissociated by trituration and plated as a single-cell suspension on Primaria 
(Falcon) 35 mm dishes (106 cells/dish) in the plating medium (EMEM, Earle’s 
salts) with supplements of 10% heat-inactivated horse serum, 10% FBS, 
glutamine (2 mM, added freshly), glucose (21 mM), and bicarbonate (38 mM). 
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After 5–7 days in vitro, non-glial cell division was stopped by 1–3 day of 
exposure to 10-5 M cytosine arabinoside. The cells were moved into a 
maintenance medium similar to the plating medium, but lacking FBS. 
Subsequently, the medium was replaced on a biweekly schedule. The culture 
medium did not contain glutamate, except for that present in the serum. Based on 
the supplier’s measurement of serum glutamate levels, the initial glutamate 
concentration in the maintenance medium was less than 20 mM.
3. Cell irradiation
X-rad 320 (Precision X-Ray, North Branford, CT, USA) was used, 
operating at 320 kVp and 12.5 mA with 2.0 mm Al filtration and a dose rate of 
4.76 cGy/sec.
4. Western blotting
The cells were washed twice with cold phosphate buffered saline (PBS) 
and lysed at 4°C for 15 minutes in PBS containing 1% Triton X-100 and the 
complete protease inhibitor mixture (Roche). The cell lysates were then cleared 
by centrifugation at 12,000 ´ g for 10 minutes at 4°C and protein concentrations 
were determined. The protein samples were resolved by SDS-polyacrylamide gel 
electrophoresis and transferred onto polyvinylidene fluoride membranes. The 
membranes were blocked with 0.5% non-fat milk plus 0.1% Tween 20 for 1 hour. 
After blocking, the membranes were incubated overnight at 4°C in primary 
antibodies, including an anti-human xCT (rabbit polyclonal antibody, ab37185, 
Abcam, Tokyo, Japan) (1:1000). Membranes were rinsed at least three times 
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with tris-buffered saline (TBS) and tween 20 (TBST) from 5 minutes each and 
were then incubated in 1% non-fat milk containing a horseradish peroxidase 
(HRP) conjugated secondary antibody for 2 hours at room temperature. After the 
final TBST wash, the membranes were suspended in an enhanced 
chemiluminescence solution (Pierce, Rockford, IL, USA) and exposed on film. 
Western blots were then scanned.44
5. Measurement of intracellular GSH level
Intracellular GSH levels were measured using the GSH assay kit (GSH-
Glo™ Glutathione Assay, Promega, Madison, WI, USA) according to the 
manufacturer’s instructions. Briefly, the medium from the wells of a 96-well 
plate was removed after plating cells and performing the required treatments. 
Then, 100 μL of prepared 1X GSH-Glo™ Reagent was added to each well. After, 
30 minutes of incubation at room temperature, 100 μL of reconstituted Luciferin 
Detection Reagent was added to each well. After mixing briefly on a plate shaker, 
the plate was incubated for 15 minutes. Thereafter, the luciferase activity was 
measured by using a luminometer.
6. RNA preparation and cDNA conversion
For RNA preparation (RNeasy mini kit, Qiagen, Hilden, Germany), cells 
were disrupted in 600 μL of RLT buffer. The lysate was then centrifuged for 3 
minutes in order to eliminate everything, but the supernatant. After adding 1 
volume of 70% ethanol to the cleared supernatant, the sample was transferred to 
the RNeasy spin column and centrifuged at 8,000 ´ g for 15 sec. The RNeasy 
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spin column was centrifuged two more times at 8000 ´ g for 15 sec – once after 
adding 700 μL of RW1 buffer and again after adding 500 mL of RPE buffer. 
Then, 20 μL of RNase-free water was added directly to the spin column 
membrane for RNA elution. Five hundred nanograms of RNA were used as the 
template for a 20 μL cDNA synthesis using Superscript III (Invitrogen, Carlsbad, 
CA, USA).
7. Real-time PCR
Quantitative real-time PCR was carried out to measure the mRNA levels 
of xCT and mesenchymal markers. The expression of GAPDH mRNA served as 
an internal control. The real-time PCR reactions were performed with a 7300 
Real-time PCR system (Applied Biosystems, Foster City, CA, USA) using 
fluorescent SYBR Green technology (Applied Biosystems) according to the 
manufacturer’s instructions. Unique primer pairs from coding sequences were 
specifically identified using Primer Express (Applied Biosystems). The forward 
and reverse primers used to amplify the xCT, mesenchymal markers, and
GAPDH were as follows: xCT, 5¢- CCT CTT CAT GGT TGC CCT TTC-3¢ and 
5¢-ATG ACG AAG CCA ATC CCT GTA-3¢; E-cadherin, 5¢-TGA GTG TCC 
CCC GGT ATC TTC-3¢ and 5¢-CAG TAT CAG CCG CTT TCA GAT TTT-3¢; 
occludin, 5¢-ATG GTT CAC AAA TAT ATG CCC TCT-3¢ and 5¢-TCA TCA 
TAA ATG TGT TCC TTG TCC-3¢; claudin-3, 5¢-AAC ACC ATT ATC CGG 
GAC TTC TAC-3¢ and 5¢-GTC TGT CCC TTA GAC GTA GTC CTT-3¢; snail, 
5¢-ATC GGA AGC CTA ACT ACA GC-3¢ and 5¢-CAG AGT CCC AGA TGA
GCA TT-3¢; vimentin, 5¢-CGT ACG TCA GCA ATA TGA AAG TGT-3¢ and 5¢-
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GTG TCT TGG TAG TTA GCA GCT TCA-3¢; fibronectin, 5¢-AAG AGA CAG 
CTG TAA CCC AGA CTT-3¢ and 5¢-AAG TGC AAT CAG TGT AAT TGT 
GGT-3¢; alpha-smooth muscle actin (alpha-SMA), 5’-GAC AAT GGC TCT 
GGG CTC TGT AA-3’ and 5’-ATG CCA TGT TCT ATC GGG TAC TT-3’; 
Fibroblast activation protein (FAP), 5’- GTA TTT GGA GTT GCC ACC TCT 
G-3’ and 5’- GAA GGG CGT AAG ACA ATG CAC-3’; GAPDH, 5¢-CCT CGA 
GAA ACC TGC CAA GTA T-3¢ and 5¢-CTC GGC CGC CTG CTT-3¢. Real-
time PCR was carried out on 2 μL of cDNA synthesized from 200 ng of total 
RNA. The ubiquitously expressed GAPDH was used as an endogenous control. 
The ratio of mesenchymal markers expression to GAPDH gene expression 
represents the relative expression level of mesenchymal markers. The 2-ΔΔCT 
method was used to quantify the relative change.
8. γ-H2AX focus formation
For the γ-H2AX focus formation assay, 45 cells were plated on coverslips. 
Before irradiation, the cells were mock-treated with Dimethyl sulfoxide (DMSO) 
or treated with 0.25 mM sulfasalazine for 24 hours. The cells were irradiated 
with 2 or 10 Gy using X-RAD 320 (Precision X-Ray). After irradiation, the cells 
were fixed in 4% paraformaldehyde and incubated overnight with an anti-γ-
H2AX antibody (Millipore, Darmstadt, Germany). Cells were incubated in the 
dark with an FITC-labeled secondary antibody for 1 hour and then incubated in 
the dark with 4,6-diamidino-2-phenylindole (DAPI) for 10 minutes. Coverslips 
were then mounted with an antifade solution. Detection of fluorescence and 
acquisition of images were performed with a Zeiss LSM 700 confocal 
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fluorescence microscope. For each treatment condition, γ-H2AX foci were 
determined in at least 100 cells.
9. Clonogenic (colony formation) assay
Clonogenic assay for radiation survival experiments was performed as 
previously described.45,46 Cells were plated in triplicate per data point into 6-well 
plates and then allowed to attach. Before irradiation, the cells were mock-treated 
with DMSO or treated with 0.25 mM sulfasalazine for 24 hours. The cells were 
irradiated with graded doses of X-rays, 0, 2, 4, and 6 Gy, using X-RAD 320. 
Immediately after irradiation, the cells were incubated in drug-free medium for 
10–14 days to allow for the formation of colonies. Thereafter, the cells were 
stained with 0.5% crystal violet. The colonies were counted with a cutoff value 
of 50 viable cells, providing the percentage of survival as a function of the 
irradiation dose. The cell survival curve is defined as a relationship between the 
doses of the agent used to produce an insult and the fraction of cells retaining 
their ability to reproduce and calculated using a percentage of survival as a 
function of the dose. Thus, I calculated the plating efficacy (PE) and surviving 
fraction (SF). The PE is the ratio of the number of colonies to the number of cells 
seeded from the non-irradiated control plate. The SF is defined as the number of 
colonies that arise after treatment of the cells divided by the number of cells 
seeded multiplied by PE.
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10. Wound healing (in vitro scratch) assay
Monolayer wound-healing (in vitro scratch) assay was performed by 
plating cells in 6-well plates according to previous studies.47 Cells were seeded to 
confluence or near confluence (>90%) into 6-well plates. The confluent 
monolayers were scratched using a pipette tip. This allows imaging of both 
wound edges using the 10´ objective of a light microscope. Thereafter, cells, 
which migrated after 24 hours, were imaged under the 10´ objective and 
analyzed.
11. MTT cell viability assay
To evaluate the effect of system xc- inhibition on cell viability, cell 
viability was measured using 3-(4,5-Dimethyl-2-thiazolyl)-2,5-diphenyl-2H-
tetrazolium bromide (MTT) according to the manufacturer’s protocol (Dojindo 
Molecular Technologies, INC., Munich, Germany). A total of 5000 cells were 
plated in each well of 96-well plate with 100 μL of growth medium. After 
incubation for 24 hours in a CO2 incubator following sulfasalazine treatment and 
irradiation with 10 Gy, 10 μL of MTT solution were added to each well. The 
plate was incubated at 37°C for 3 hours. Thereafter, 100 μL of DMSO was added 
to dissolve the resulting MTT formazan. The absorbance was measured at 520–
600 nm with a microplate reader.
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12. Immunohistochemistry
Immunohistochemistry was performed using 3,3'-Diaminobenzidine (DAB) 
peroxidase substrate kit (SK-4100, Vector Laboratories, Inc., CA, USA). I
obtained the human paraffin embedded tissue sections presenting proneural and 
mesenchymal glioblastoma from Professor S.H. Kim at the department of 
pathology in Yonsei University College of Medicine. For deparaffinization, 
slides were incubated in xylene for 24 hours at room temperature. Thereafter, the 
slides were incubated in fresh xylene for 15 minutes. This step was repeated. The 
slides were then incubated in 100%, 95%, 90%, 80%, and 70% ethanol for 15 
minutes and then in distilled water for 5 minutes. The slides were incubated at 
100°C for 20 minutes in 0.01 M sodium citrate buffer for antigen retrieval and 
then multiple washes were performed in PBS with gentle shaking. The slides 
were incubated in oxidation blocking buffer (200 mL methanol and 3 mL of 30% 
hydrogen peroxide) at room temperature. Thereafter, slides were washed three 
times in PBS for 5 minutes each. Each section was blocked with 400 µL 
blocking solution for 1 hour at room temperature in a humidified chamber. The 
blocking solution was removed and 400 µL of primary antibody against xCT 
(1:400, rabbit, polyclonal, abcam, Cambridge, UK) diluted in blocking solution 
was added to each section. The slides were incubated overnight at 4°C in a 
humidified chamber. After removal of the primary antibody solution, the slides 
were washed in PBS three times for 5 minutes each. Then, 400 µL of 
biotinylated secondary antibody (rabbit) in blocking solution was added and 
incubated for 1 hour at room temperature in a humidified chamber. After 3 
washes with PBS, signal amplification was performed using the avidin-biotin 
complex (ABC) according to manufacturer’s instructions (PK-6101, Vector 
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Laboratories, Inc.). The ABC complex solution (500 µL) was added to each 
section and incubated 1 for hour at room temperature in a humidified chamber. 
After 3 washes in PBS, 400 µL of DAB solution was added to each section and
monitored closely. After 1–2 minutes, acceptable staining intensity was obtained. 
The slides were immediately washed in PBS three times for 10 minutes each. 
Dehydration was then performed by incubation in 50%, 75%, 95%, 100% 
ethanol for 5 minutes and xylene for 20 minutes. At last, the samples were 
mounted with the Fisher PermountTM mounting medium and cover glasses 
(SP15-100, Fisher scientific, Pittsburgh, PA, USA).
13. Statistical analysis
All data are presented as mean ± standard error of the mean (SEM). Data 
were analyzed with regard to statistical significance using an independent-
samples t test and one-way analysis of variance followed by Bonferroni post-hoc 
test. A p-value <0.05 was considered to be statistically significant.
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III. RESULT
1. System xc
- inhibition and improved radio-sensitivity in vitro
A. System xc
- inhibition in glioblastoma in vitro
(A) Sulfasalazine inhibits xCT from system xc
- in glioblastoma in 
vitro
I used sulfasalazine as a potent selective competitive inhibitor of system 
xc-. After system xc- inhibition with sulfasalazine, the expression of xCT, the light 
chain of system xc-, was suppressed in A172 and U87-MG (Figure 3A). I also 
observed that xCT mRNA expression was significantly elevated by the decrease 
in xCT protein expression compared to controls (Figure 3B, p < 0.001 in both 
cell lines).
(B) xCT inhibition induces a decrease in intracellular GSH levels in 
glioblastoma in vitro
To investigate whether system xc
- inhibition induces a decrease in 
intracellular GSH levels, I measured intracellular GSH levels in glioblastoma
and astrocytes System xc- inhibition by sulfasalazine caused a dose-dependent 
reduction of GSH levels in A172 and U87-MG cells. At 24 hours following SAS 
treatment, the intracellular GSH levels decreased as the dose increases in both 
cells (Figure 4A, p < 0.001). After 0.25 mM sulfasalazine treatment, the 
intracellular GSH levels decreased as time goes on in both cells (Figure 4B, p 
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<0.001). The depletion in intracellular GSH by sulfasalazine was also observed 
in astrocytes. However, sulfasalazine only had a small effect on astrocytes 
(Figure 4C, p < 0.001).
Figure 3. System xc
- inhibition by sulfasalazine (SAS) in glioblastoma and 
astrocytes. (A) We performed the immune-blotting to evaluate the protein 
expression of xCT in GBM in vitro. After system xc- inhibition with SAS, the 
expression of xCT, the light chain of system xc-, was suppressed in A172 and 
U87-MG. (B) We performed the real-time PCR to investigate the change of xCT
mRNA expression at 24 hours after the treatment of SAS (0.25mM) in GBM in 
vitro. xCT mRNA expression of SAS group was significantly elevated by the 
decrease of xCT protein expression compared to control (***p < 0.001).
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(C) Dose determination using the cell viability assay 
Cell viability assays were performed to determine the proper dose of 
sulfasalazine. The cell viability of A172 (Figure 5A, p = 0.082) and U87-MG 
cells (Figure 5B, p = 0.171) treated with 0.25 mM sulfasalazine was not 
significantly different from that of control cells. At 0.5 mM sulfasalazine was 
significantly more cytotoxic in both glioblastoma cell lines (A72 cells, Figure 5A, 
p < 0.001); U87-MG cells, Figure 5B, p < 0.001). Thus, a dose of 0.25 mM 
sulfasalazine was used to evaluate the radio-sensitizing effect of system xc-
inhibition.
B. Irradiation combined with system xc- inhibition increased DSB 
compared to irradiation alone in glioblastoma in vitro
To evaluate whether the combination of irradiation with system xc-
inhibition could elevate DNA damage, I performed the γ-H2AX focus formation 
assay to detect DNA damage. The induction of DNA DSB is followed by the 
formation of γ-H2AX foci, which are phosphorylated H2AX molecules in the 
chromatin flanking the DSB site. Twenty-four hours after treatment with 0.25 
mM sulfasalazine, cells were irradiated with 2 and 10 Gy. The γ-H2AX was 
stained in green and the nucleus was stained in blue by DAPI (Figure 6A). Each 
γ-H2AX focus represents one radiation-induced DSB. Irradiation combined with 
sulfasalazine treatment induced a significant increase in γ-H2AX foci at each 
dose of irradiation in both glioblastoma cell lines (Figure 6A). I quantified the 
number of γ-H2AX foci per nucleus (Figure 6B and 6C). The combination of 
irradiation with sulfasalazine significantly increased the number of γ-H2AX foci 
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when compared to irradiation alone, regardless of the irradiation dose in both 
A172 (Figure 6B, p < 0.001) and U87-MG cells (Figure 6C, p < 0.001). 
C. System xc
- inhibition enhanced radio-sensitivity in glioblastoma in 
vitro
Next, I conducted clonogenic assays to evaluate the effects of system xc
-
inhibition on radio-sensitivity. The clonogenic cell survival assay, known as 
colony formation assay, determines the ability of a cell to proliferate indefinitely, 
thereby retaining its reproductive ability to form a large colony or a clone 
(Figure 7A). This cell is then considered clonogenic. The combination of 
irradiation and sulfasalazine treatment inhibited clonogenicity when compared to 
irradiation alone, when a 6 Gy irradiation was delivered (Figure 7A). In the 
irradiation plus sulfasalazine group, the surviving cell fraction was lower than 
that of the irradiation alone group at each dose in A172 cells (Figure 7B, p < 
0.001) and in U87-MG cells (Figure 7C, p < 0.001).
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Figure 4. Decrease in intracellular GSH induced by xCT inhibition in 
glioblastoma. (A) and (B) We measured the intracellular GSH induced by 
system xc- inhibition. System xc- inhibition by sulfasalazine (SAS) causes a dose 
(A)- and time (B)- dependent reduction in GSH levels in A172 and U87-MG 
cells (***p < 0.001). (C) Despite the depletion of intracellular GSH in astrocytes
at 24 hours following SAS treatment, SAS only had a small effect on astrocytes
(***p < 0.001).
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Figure 5. Determination of the sulfasalazine (SAS) dose in A172 and U87-
MG cells. We performed the MTT assay to determine the proper dose of SAS 
based on cell viability. The cell viability of the cells treated with 0.25 mM SAS 
was not significantly different from that of the control in A172 (A) and U87-MG 
(B). However, 0.5 mM SAS was significantly more cytotoxic compared to 
control and 0.25 mM SAS in both cell lines (***p < 0.001).
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Figure 6. The combination of irradiation with sulfasalazine (SAS) treatment 
increased DSB in glioblastoma. The γ-H2AX foci formation assay was 
performed to evaluate the DNA DSB in each group. (A) Cells were irradiated 
with 2 and 10 Gy 24 hours following SAS (0.25 mM) treatment. γ-H2AX is 
stained in green and the nucleus is stained in blue by DAPI. Each γ-H2AX focus 
represents one radiation-induced DSB. (B) and (C) The combination of 
irradiation with SAS treatment significantly increased the number of γ-H2AX 
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foci compared to irradiation alone, regardless of the irradiation dose in both cell 
lines (***p < 0.001 in both cell lines).
Figure 7. System xc
- inhibition enhanced radio-sensitivity in glioblastoma. (A) 
I performed the colony formation assay to investigate the radio-sensitivity 
according to the system xc- inhibition using A172 and U87-MG cells. (B) and (C) 
Survival curves based on colony formation assay. In the irradiation plus 
sulfasalazine group, the surviving cell fraction was lower than that of the 
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irradiation plus DMSO group at each dose in A172 (B) and U87-MG cells (C) 
(***p < 0.001).
D. Summary
The combination of irradiation and inhibition of system xc
- induced a 
significant increase in DSB and a significant decrease of the surviving cell 
fraction compared to irradiation alone in glioblastoma. In conclusion, my
findings demonstrated that irradiation combined with system xc- inhibition could 
improve radio-sensitivity compared to irradiation alone in glioblastoma.
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2. System xc
- inhibition and cell migration through the change of 
mesenchymal markers
A. System xc
- inhibition reduced the cell migration in glioblastoma in 
vitro
Wound healing (scratch) assay was conducted to investigate whether the 
combination of irradiation with sulfasalazine treatment could affect cell 
migration. In A172 and U87-MG cells, cells from the control and irradiation 
alone groups migrated more than cells from the sulfasalazine group with or 
without irradiation after 24 hours following the completion of irradiation (Figure 
8A). Quantification of cell migration in both cell lines showed that the addition 
of sulfasalazine significantly prevented cell movement irrespectively of 
irradiation (Figure 8B and 8C, p < 0.001 in both cell lines). Cell migration was 
significantly higher in the irradiation alone group than in the control group 24 
hours following the completion of irradiation in both cell lines (p < 0.001 in both 
cell lines). Despite the increase in migration induced by irradiation, the degree of 
inhibition of cell migration by sulfasalazine in the irradiation group was similar 
to that in the sulfasalazine alone group 24 hours after irradiation in both cell lines 
(p = 0.124 in U87-MG and p > 0.99 in A172). 
To evaluate whether sulfasalazine cytotoxicity would affect the 
quantification of cell migration, I measured cell viability (Figure 9A and 9B). 
After 24 hours following the completion of irradiation in both cell lines, the rates 
of cell viability between all groups were not significantly different (p > 0.05 in 
both cell lines).
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Figure 8. System xc
- inhibition reduced cell migration in glioblastoma. (A) 
We performed the wound healing assay to evaluate the cell migration. In both 
cell lines, cell migration was higher in the control and irradiation alone groups 
than in the sulfasalazine group with or without irradiation after 24 hours 
following the completion of irradiation. (B) and (C) Quantification of cell 
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migration in both cell lines showed that the addition of sulfasalazine significantly 
prevented cell movement irrespective of irradiation after 24 hours following the 
completion of irradiation (***p < 0.001). Cell migration was significantly higher 
in the irradiation alone group than in the control group for both cell lines (†††p < 
0.001). The degree of inhibition of cell migration by sulfasalazine in the 
irradiation group was similar to that of the sulfasalazine alone group (p > 0.99 
for A172 cells and p = 0.124 for U87-MG cells).
B. System xc- inhibition decreased the expression levels of 
mesenchymal markers in glioblastoma in vitro
(A) IR increased the expression of the TCGA-based mesenchymal 
markers, CD44 and YKL-40 in glioblastoma in vitro
To evaluate whether irradiation could induce the mesenchymal transition, I
evaluated the change in TCGA-based mesenchymal markers, CD44 and YKL-40, 
after irradiation. I performed RT-PCR using RNA from A172 and U87-MG cells 
after irradiation with 10 Gy. Irradiation significantly elevated CD44 expression 
in A172 (p < 0.01) and U87-MG cells (p < 0.05) (Figure 10A) as well as YKL-40
expression in both glioblastoma cell lines (Figure 10B, p < 0.05 in both cell 
lines). 
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Figure 9. Sulfasalazine cytotoxicity did not affect the cell migration. (A) and 
(B) After 24 hours following the completion of irradiation in both cell lines, the 
rates of cell viability by sulfasalazine (SAS) between all groups were not 
significantly different (p > 0.05 in both cell lines).
(B) System xc- inhibition decreased the mRNA expression of 
mesenchymal markers in glioblastoma in vitro
To investigate whether system xc- inhibition was associated with changes 
in mesenchymal markers in glioblastoma, I evaluated the mRNA expression of 
mesenchymal markers, SNAIL, vimentin, and N-cadherin. SNAIL mRNA 
expression in the irradiation group was significantly higher than that of the 
control group at 6 and 24 hours after irradiation in A172 cells (Figure 11A, p <
0.001). However, SNAIL mRNA expression in the irradiation plus sulfasalazine
group was significantly lower than that of the irradiation group (Figure 11A, p < 
0.001). Sulfasalazine alone also significantly decreased SNAIL mRNA level 
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compared to that of the control group (Figure 11A, p < 0.01). Figure 11B depicts 
similar findings obtained in U87-MG cells. SNAIL mRNA expression was 
significantly higher in the irradiation group than in the control group at 6 and 24 
hours after irradiation in U87-MG cell (p < 0.001). SNAIL mRNA expression in 
the irradiation plus sulfasalazine group was significantly lower than that of the 
irradiation group (p < 0.001). Sulfasalazine alone also significantly decreased 
SNAIL mRNA level when compared to that of the control group (p < 0.05).
Figure 10. Irradiation increased the expression of TCGA-based 
mesenchymal markers, CD44 and YKL-40. We performed the real-time PCR 
to evaluate whether irradiation could increase the TCGA-based mesenchymal 
markers, CD44 and YKL-40, after irradiation. (A) Irradiation significantly 
elevated the expression of CD44 in A172 (**p < 0.01) and U87-MG cells (*p < 
0.05) compared to control. (B) Irradiation significantly increased YKL-40 
expression in both glioblastoma cell lines (*p < 0.05 in both cell lines) compared 
to control.
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Figure 11. System xc
- inhibition decreased the SNAIL mRNA expression in 
glioblastoma. We performed the real-time PCR to evaluate the mRNA 
expression of SNAIL (A) SNAIL mRNA expression in the irradiation group was 
significantly higher than that of the control group at 6 and 24 hours after 
irradiation in A172 cells (†††p < 0.001). However, SNAIL mRNA expression in 
the irradiation plus SAS group was significantly lower than that of the irradiation 
group (***p < 0.001). SAS alone also significantly decreased SNAIL mRNA level 
compared to that of the control group (##p < 0.01). (B) SNAIL mRNA expression 
was significantly higher in the irradiation group than in the control group at 6 
and 24 hours after irradiation in U87-MG cell (†††p < 0.001). SNAIL mRNA 
expression in the irradiation plus SAS group was significantly lower than that of 
the irradiation group (***p < 0.001). SAS alone also significantly decreased 
SNAIL mRNA level compared to the control group (#p < 0.05).
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Figure 12. System xc
- inhibition decreased vimentin mRNA expression in 
glioblastoma. We performed the real-time PCR to evaluate the mRNA 
expression of vimentin (A) Vimentin mRNA expression in the irradiation group 
was significantly higher than that of the control group at 6 and 24 hours after 
irradiation in A172 cells (†††p < 0.001). However, vimentin mRNA expression in 
the irradiation plus SAS group was significantly lower than that of the irradiation 
group (***p < 0.001). SAS alone also significantly decreased vimentin mRNA 
level compared to that of the control group (#p < 0.05). (B) Vimentin mRNA 
expression was significantly higher in the irradiation group than in the control 
group at 6 and 24 hours after irradiation in U87-MG cell (†††p < 0.001). Vimentin 
mRNA expression in the irradiation plus SAS group was significantly lower than 
that of the irradiation group (***p < 0.001). SAS alone also significantly decreased 
vimentin mRNA level compared to the control group (#p < 0.05).
Vimentin mRNA fold change was similar to that of SNAIL in both cell 
lines (Figure 12). My findings demonstrated that vimentin mRNA expression 
was significantly higher in the irradiation group than in the control group at 6 
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and 24 hours after irradiation in both glioblastoma (Figure 12A and 12B, p <
0.001). However, vimentin mRNA expression was significantly lower in the 
irradiation plus sulfasalazine group than in the irradiation group (Figure 12A and 
12B, p < 0.001). Sulfasalazine alone also significantly decreased vimentin 
mRNA level when compared to the control group in both glioblastoma cell lines 
(Figure 12A and 12B, p < 0.05). 
N-cadherin mRNA expression was also significantly higher in the 
irradiation group than in the control group in both cell lines after 6 and 24 hours 
following the completion of irradiation (Figure 13A and 13B, p < 0.001). The 
irradiation plus sulfasalazine group showed a significantly lower N-cadherin 
mRNA expression than the irradiation group in both cell lines (Figure 13A and 
13B, p < 0.001). However, N-cadherin mRNA expression was not significantly 
different between the sulfasalazine alone and the control groups in both cell lines, 
except for the significant difference at 24 hours after irradiation in U87-MG cells 
(Figure 13B, p < 0.01). 
There was no difference of alpha-SMA mRNA expression between all 
groups in A172 cells (Figure 14A). There was also no difference of alpha-SMA 
mRNA expression between all groups at 6 hours after irradiation in U87-MG cell 
(Figure 14B). However, alpha-SMA mRNA expression was significantly higher 
in the irradiation group than in the control group at 24 hours after irradiation 
(Figure 14B, p < 0.001). Alpha-SMA mRNA expression in the irradiation plus 
SAS group was significantly lower than that of the irradiation group (Figure 14B, 
p < 0.01). SAS alone significantly decreased alpha-SMA mRNA level compared 
to the control group at 24 hours after irradiation (Figure 14B, p < 0.01).
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Figure 13. System xc
- inhibition decreased N-cadherin mRNA expression in 
glioblastoma. We performed the real-time PCR to evaluate the mRNA 
expression of N-cadherin (A) N-cadherin mRNA expression in the irradiation 
group was significantly higher than that of the control group at 6 and 24 hours 
after irradiation in A172 cells (†††p < 0.001). However, N-cadherin mRNA 
expression in the irradiation plus SAS group was significantly lower than that of 
the irradiation group (***p < 0.001). (B) N-cadherin mRNA expression was 
significantly higher in the irradiation group than in the control group at 6 and 24 
hours after irradiation in U87-MG cell (†††p < 0.001). N-cadherin mRNA 
expression in the irradiation plus SAS group was significantly lower than that of 
the irradiation group (***p < 0.001). SAS alone significantly decreased N-
cadherin mRNA level compared to the control group at 24 hours after irradiation 
(##p < 0.05). 
40
Similar to alpha-SMA, there was no difference of FAP mRNA expression 
between all groups at 6 hours after irradiation in A172 cells. FAP mRNA 
expression was significantly higher in the irradiation group than in the control 
group at 24 hours after irradiation (Figure 15A, p < 0.05). FAP mRNA 
expression in the irradiation plus SAS group was significantly lower than that of 
the irradiation group (Figure 15A, p = 0.01). There was no difference of FAP 
mRNA expression between all groups at 6 hours after irradiation in U87-MG cell, 
similarly. Otherwise, FAP mRNA expression was significantly higher in the 
irradiation group than in the control group at 24 hours after irradiation (Figure 
15B, p < 0.001). FAP mRNA expression in the irradiation plus SAS group was 
significantly lower than that of the irradiation group (Figure 15B, p < 0.001).
To evaluate whether sulfasalazine cytotoxicity would affect mRNA 
expression, I measured cell viability (Figure 16A and 16B). After 6 hours 
following the completion of irradiation in both cells, the rates of cell viability 
between all groups were not significantly different (p > 0.05 in both cell lines).
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Figure 14. System xc
- inhibition decreased alpha-SMA mRNA expression in 
glioblastoma. We performed the real-time PCR to evaluate the mRNA 
expression of alpha-SMA (A) There was no difference of alpha-SMA mRNA 
expression between all groups in A172 cells. (B) There was no difference of 
alpha-SMA mRNA expression between all groups at 6 hours after irradiation in 
U87-MG cell. Alpha-SMA mRNA expression was significantly higher in the 
irradiation group than in the control group at 24 hours after irradiation (†††p < 
0.001). Alpha-SMA mRNA expression in the irradiation plus SAS group was 
significantly lower than that of the irradiation group (**p < 0.01). SAS alone 
significantly decreased alpha-SMA mRNA level compared to the control group 
at 24 hours after irradiation (##p < 0.01).
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Figure 15. System xc
- inhibition decreased FAP mRNA expression in 
glioblastoma. We performed the real-time PCR to evaluate the mRNA 
expression of FAP (A) There was no difference of FAP mRNA expression 
between all groups at 6 hours after irradiation in A172 cells. FAP mRNA 
expression was significantly higher in the irradiation group than in the control 
group at 24 hours after irradiation (†p < 0.05). FAP mRNA expression in the 
irradiation plus SAS group was significantly lower than that of the irradiation 
group (**p = 0.01). (B) There was no difference of FAP mRNA expression 
between all groups at 6 hours after irradiation in U87-MG cell. FAP mRNA 
expression was significantly higher in the irradiation group than in the control 
group at 24 hours after irradiation (†††p < 0.001). FAP mRNA expression in the 
irradiation plus SAS group was significantly lower than that of the irradiation 
group (***p < 0.001). 
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(C) System xc
- protein expression was higher in mesenchymal 
glioblastoma than in proneural glioblastoma
In addition, I investigated whether xCT protein expression level was 
related to the mesenchymal type of glioblastoma (Figure 17). I performed 
immunohistochemistry on human normal brain, and human proneural or 
mesenchymal glioblastoma tissues. xCT protein expression was observed by 
DAB staining. Hematoxylin was utilized for counterstaining. Normal brain tissue 
had a weak xCT protein expression. Similar to normal brain, one case of 
proneural glioblastoma presented a weak xCT protein expression, although xCT 
expression was induced by gliosis. However, three cases of mesenchymal 
glioblastoma showed a stronger xCT protein expression than cases of proneural 
glioblastoma.
C. Summary
I observed that irradiation could induce the increase of mesenchymal 
markers in glioblastoma. My findings demonstrated that system xc- inhibition 
could reduce the irradiation-induced cell migration in glioblastoma. System xc-
inhibition decreased mesenchymal markers in glioblastoma. System xc
- protein 
expression was higher in mesenchymal glioblastoma specimens than in proneural 
glioblastoma and normal brain specimens.
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Figure 16. Sulfasalazine cytotoxicity did not affect mRNA expression. To 
evaluate whether sulfasalazine (SAS) cytotoxicity would affect mRNA 
expression, cell viability was measured in A172 and U87-MG cells (A and B). 
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Figure 17. The expression of system xc
- protein was higher in mesenchymal 
glioblastoma than in proneural glioblastoma tissues. Immunohistochemistry 
was performed on human normal brain, and human proneural or mesenchymal 
glioblastoma tissues. xCT expression was observed by DAB staining. 
Hematoxylin was utilized for counter staining. The upper and lower panels are 
images acquired at the 4´ and 20´ objectives, respectively. Norma brain tissue 
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showed a weak xCT expression. Similarly, specimens from patients with 
proneural glioblastoma presented a weak xCT protein expression, despite the 
mild elevation of xCT expression induced by gliosis. However, specimens from 
patients with mesenchymal glioblastoma presented a stronger xCT protein 
expression.
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IV. DISCUSSION
This study demonstrated that system xc
- inhibition can reduce intracellular 
cystine uptake and the resulting production of GSH. The combination of irradiation 
with system xc
- inhibition significantly increased DSB and significantly decreased 
the surviving cell fraction compared to irradiation alone in glioblastoma. My
findings showed that the combination of irradiation with system xc- inhibition 
enhances radio-sensitivity compared to irradiation alone in glioblastoma. My
findings also demonstrated that irradiation induces cell migration through the 
changes in mesenchymal markers in glioblastoma. System xc- inhibition reduces the 
irradiation-induced cell migration in glioblastoma and decreases the expression of 
representative mesenchymal markers in glioblastoma. System xc- strong protein 
expression was significantly related to mesenchymal glioblastoma compared to 
proneural glioblastoma in human glioblastoma specimens.
My results indicate that system xc- inhibition by sulfasalazine reduces xCT 
protein expression and the intracellular uptake level of GSH in glioblastoma. xCT
mRNA expression level increased after system xc- inhibition. I believe that this 
finding is linked to the appropriate inhibition of system xc- by sulfasalazine. 
However, there are two limitations to this conclusion. First, I did not directly 
analyze whether sulfasalazine could reduce the functional capacity of system xc
-. In 
fact, I only determined the decrease of intracellular GSH level. However, previous 
studies on system xc- inhibition utilized sulfasalazine as a specific inhibitor of 
system xc-.25,26,28,31 Furthermore, the finding that the intracellular level of GSH is 
reduced after sulfasalazine treatment supports and guarantees the inhibition of 
system xc- by sulfasalazine in most studies. Secondly, among several inhibitors of 
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system xc
-, I only used sulfasalazine. Besides sulfasalazine, sulfapyridine, 5-
aminosalicylic acid, S-(4)-CPG, and monosodium glutamate are xCT (SLC7A11) 
inhibitors as well. However, among them, sulfasalazine is the only drug currently 
used in the clinic for patients with inflammatory bowel diseases such as ulcerative 
colitis and Crohn's disease and rheumatoid arthritis.48-51 Furthermore, 2 clinical 
studies validating the effect of sulfasalazine have been performed in glioma.52,53
Robe et al. performed a phase I, II clinical trial for recurrent glioma. However, this 
trial failed to validate sulfasalazine effects for recurrent glioma, due to no treatment 
response and high rate of treatment-related toxicity, This was considered to result 
from the enrollment of patients with poor performance status.52 Takeuchi et al. also 
reported no therapeutic benefit and high incidence of hematological side effects due 
to continuous administration over several weeks.53 Although 2 clinical trials 
reported negative results, I believe that studies using sulfasalazine remain 
meaningful. Thus, this study was designed to determine the potential of 
sulfasalazine treatment. However, further studies are needed to determine the proper 
dose of sulfasalazine or to develop a new drug to inhibit system xc- in patients with 
glioblastoma. 
This study showed that xCT inhibition induced a dose- and time-dependent 
reduction of intracellular GSH in glioblastoma. In astrocytes, xCT inhibition by 
sulfasalazine reduced the intracellular GSH level in a dose- and time-dependent 
manner. However, sulfasalazine had only a small effect on astrocytes. Normally, the 
sodium-independent system xc- is mainly expressed on astrocytes and is the main 
route of cystine uptake and production of intracellular GSH in these cells.54
Glutamate released from astrocytes could be taken up by adjacent neurons to 
regulate synaptic function.55,56 If glutamate is released immoderately from 
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astrocytes, it could result in the neuro-excitotoxicity. The system xc
- mediates the 
interaction between astrocytes and neurons. Thus, I believe that xCT inhibition may 
decrease the intracellular level of GSH in astrocytes. In this study, xCT protein 
expression level in the normal brain, including glial cells, was significantly lower 
than that in human glioblastoma tissues. I think that this finding can explain why the 
degree of reduction in GSH levels in astrocytes is significantly lower than that in 
glioblastoma. Chung et al. demonstrated similar findings.9 They also depicted that 
sulfasalazine caused a time- and dose-dependent decrease in intracellular GSH in 
D54-MG glioblastoma. However, the effect of sulfasalazine treatment was 
significantly lower on intracellular levels of GSH in astrocytes.
I determined that sulfasalazine should be used at a dose of 0.25 mM based on 
cell viability assay. Previous studies used 0.5 mM sulfasalazine to inhibit xCT in 
most experiments.9,25 These studies investigated whether system xc- inhibition alone 
could prevent cancer progression and growth. In this study, I evaluated whether 
system xc- inhibition combined with irradiation could enhance radio-sensitivity 
compared to irradiation alone in glioblastoma. Thus, I needed to exclude the 
possibility that sulfasalazine alone had cytotoxic effects. My findings demonstrated 
that 0.5 mM sulfasalazine was significantly more cytotoxic than control and 0.25 
mM sulfasalazine. Furthermore, 24 hours after treatment with 0.25 mM 
sulfasalazine, the decrease in the relative intracellular GSH levels was less than 75% 
when compared to the control group in A172 and U87-MG glioblastoma. Based on 
my findings about enhanced radio-sensitivity, I consider that 0.25 mM of 
sulfasalazine would be the proper dose to investigate whether system xc- inhibition 
is related to enhanced radio-sensitivity. 
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In this study, irradiation with the xCT inhibition increased DNA DSB 
compared to irradiation alone in glioblastoma as observed using the γ-H2AX focus 
formation assay. Similar to my findings, Sleire et al. recently reported that 1 mM 
sulfasalazine and irradiation synergistically increase DNA damage in glioma cells 
by measuring γ-H2AX focus formation.57 However, my findings are different 
because irradiation with 0.25 mM sulfasalazine did not increase DNA damage when 
compared to the radiation only group. Comparing their method to mine, they 
performed the γ-H2AX focus assay 15 minutes after an 8 Gy irradiation, while I
performed the γ-H2AX focus assay 24 hours after the completion of 2 Gy and 10 
Gy irradiations. This discrepancy may explain the differences observed in term of γ-
H2AX focus assay. 
Furthermore, the clonogenic assay indicated that the surviving cell fraction of 
the irradiation plus sulfasalazine group was lower than that of the irradiation alone 
group at each dose. This method is traditionally used to test radio-sensitivity, 
because it measures the ability of individual cells to proliferate indefinitely. This 
assay allows us to determine the number of colonies formed from known numbers 
of cells, providing us with the percentage of cell survival as a function of the 
irradiation dose. The cell viability assay is also used to evaluate radio-sensitivity.58
It measures cell growth based on enzyme activity in viable cells. Live cells, 
presenting higher enzyme activity, transform the dye, resulting in a higher 
absorbance at a specific wavelength, which is directly correlated to the number of 
live cells. The cell viability assay is more rapid and less laborious than the 
clonogenic assay. However, the cell viability assay does not allow the measurement 
of indefinite proliferation. To validate itself, the cell viability assay should be 
compared to the clonogenic assay. In this study, my data from the clonogenic assay 
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validated that system xc
- inhibition enhances radio-sensitivity. Sleire et al. also 
demonstrated that sulfasalazine and irradiation synergistically increase glioma cell 
death using the MTS viability assay.57 They demonstrated that cells treated with 
0.25 mM sulfasalazine combined with irradiation showed lower cell viability 
compared to cells not treated with sulfasalazine, despite of a difference of DNA 
damage between 0.25 mM sulfasalazine and combination of 0.25 mM sulfasalazine
with irradiation. Thus, I consider that combining 0.25 mM sulfasalazine with 
irradiation could substantially enhance radio-sensitivity in glioblastoma.
I found that irradiation enhances cell migration through the increase of 
mesenchymal markers and system xc- inhibition reduces irradiation-induced cell 
migration through the increase of mesenchymal markers. Many studies also 
demonstrated radiation-induced EMT in various epithelial cancers, and radiation-
induced glial-mesenchymal transition in glioblastoma in vitro.40-42,59,60 Irradiation-
induced EMT is known to be activated by nuclear factor kappa-light-chain-enhancer 
of activated B cells (NF-kB) or transforming growth factor beta (TGF-b).59,60
Irradiation induces NF-kB activation.61 Furthermore, ROS induces EMT, which is 
mediated by NF-kB-dependent activation of SNAIL.62,63 Recently, Bhat et al.
demonstrated that mesenchymal differentiation mediated by NF-kB promotes 
radiation resistance in glioblastoma.64 Irradiation induces the TGF-b signaling 
pathway.65 Recently, Mahabir et al. demonstrated that sustained elevation of SNAIL 
promotes glial-mesenchymal transition after irradiation in malignant glioma.42 They 
showed that the expression of the mesenchymal markers vimentin, CD44, and 
YKL-40, increased in clinically recurrent malignant glioma. Additionally, 
irradiation increased CD44 and YKL-40 expression in glioblastoma and induced the 
glial-mesenchymal transition. Thus, I believe that the increase in ROS induced by 
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the combination of irradiation with system xc
- inhibition could promote the 
mesenchymal transition through either NF-kB or TGF-b, which could result in 
radio-resistance and treatment-failure. However, using the wound healing assay, I
found that the combination of sulfasalazine with irradiation reduced cell migration 
and the expression of mesenchymal markers such as vimentin, N-cadherin, SNAIL, 
alpha-SMA and FAP when compared to the irradiation only group. Therefore, I
consider that the combination of system xc- inhibition and irradiation could enhance 
local therapeutic effects by improving radio-sensitivity and concurrently reducing 
migration and invasion of glioblastoma through inhibition of the increase of 
mesenchymal markers.
Thus, I investigated whether xCT protein expression level was related to the 
mesenchymal type of glioblastoma in human tissues by immunohistochemistry. I
observed that the xCT protein expression was significantly higher in mesenchymal 
than in proneural human glioblastoma specimens. Several studies showed that xCT 
protein expression is significantly stronger in tumors than in normal brain tissues.8,57
However, no study demonstrated differences in xCT protein expression based on 
genomic subtypes of glioblastoma. This study is the first to describe a difference in 
xCT protein expression based on genomic subtypes of glioblastoma. Furthermore, 
because the mesenchymal glioblastoma is known to have the worst prognosis 
among the genomic subtypes of glioblastoma, I consider that this points could imply 
the clinical availability of combination therapy of system xc- inhibition and RT in 
primary or recurrent mesenchymal glioblastoma. Although further clinical trials to 
investigate the survival benefit of combination therapy of system xc- inhibition and 
RT in mesenchymal glioblastoma patients, I suggest that my study open up the 
exciting prospects to improve the survival in mesenchymal glioblastoma.
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IV. CONCLUSION 
In conclusion, my findings demonstrate that system xc
- inhibition in 
combination with irradiation increased DNA damage and enhance radio-sensitivity 
in glioblastoma. Furthermore, system xc
- inhibition prevented the IR-induced cell 
migration and affected mesenchymal features in glioblastoma. I believe that the
combination of RT and system xc- inhibition could help improve glioblastoma
therapeutic outcome.
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Abstract (IN KOREAN)
교모세포종에서 cystine/glutamate transporter (system xc
-)의
억제에 의한 방사선 감수성 향상 및 종양 증식 억제 효과
<지도교수 김 철 훈>
연세대학교 대학원 의과학과
윤 홍 인
교모세포종은 근치적 절제술 후 방사선 치료 및 테모졸로마이드
(Temozolomide)의 병용 치료에도 불구하고 가장 예후가 불량한 뇌
종양으로 이를 극복하기 위한 새로운 치료 방침이 필요하다.
System xc
-는 1 대 1 비율로 글루타메이트 (glutamate)를 세포 밖으
로 내보냄과 동시에 시스틴 (cystine)을 세포 안으로 흡수하는 수
송체로, xCT (SLC7A11)라는 경쇄 (light-chain subunit)와 CD98hc 
(SLC3A2)라는 중쇄 (heavy chain subunit)로 구성되어 있다.
System xc
-에 의해 흡수된 세포 내 시스틴은 세포 안에서 가장 중
요한 항산화제 (antioxidant)인 글루타티온 (glutathione, GSH)을
합성한다. 이는 교모세포종을 포함한 암세포의 생존과 증식에 기
여함이 익히 알려져 있다. 이에 system xc
-의 억제가 방사선 치료
와 병용하였을 때, 방사선으로 인한 활성산소 (reactive oxygen 
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species)에 의한 방사선 치료 효과가 증대되고, 종양 증식을 억제
시키는 효과도 가져올 수 있다고 가설을 설정하였다.
이 연구는 system xc
-의 억제가 교모세포종의 방사선 감수성을 증
가시키고, 교모세포종의 증식과 주변 침범을 억제할 수 있음을 보
여주었다. System xc
-의 억제는 교모세포종 세포주들에서 세포 내
클루타티온의 감소를 유도하며, 방사선과 병용시 방사선 단독 처
치 군보다 교모세포종 세포들의 디옥시리보핵산 (DNA) 두 가닥 파
손(DSB; double strand break)의 양을 증가시켰다. 또한 각 방사
선 조사량에서 system xc
-를 억제한 군의 생존 분획 (surviving 
fraction)이 유의하게 낮았다.
한편, 방사선은 교모세포종에서 간엽성 (mesenchymal) 이행
(transition) 표지자들을 증가시켜서 세포 이동을 증가시킬 수 있
는데, 이 연구에서 그 증거로 우리는 방사선 조사 후 교모세포종
세포주에서 간엽성 교모세포종의 The Cancer Genome Atlas (TCGA) 
표지자 (marker)인 CD44 와 YKL-40 의 발현량이 증가함을 제시하였
다. 방사선으로 인한 간엽성 이행 표지자인 CD44 와 YKL-40 의 발
현량 증가가 관찰된 교모세포종 세포주에서 system xc
-의 억제가
교모세포종의 세포 이동을 억제하였다. 그리고 system Xc- 억제는
교모세포종에서 간엽성 표지자인 SNAIL, vimentin, N-cadherin, 
alpha-SMA 와 FAP 를 유의하게 감소시켰다. 추가로, 교모세포종 환
자의 수술 조직을 이용한 면역 조직 화학 염색 실험에서, system 
xc
-의 발현량이 예후가 좋지 않은 간엽성 교모세포종에서 높았음을
관찰하였다.
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결론적으로 이 연구는 system xc
-의 억제가 방사선과 병용하였을
때 시스틴의 흡수와 글루타티온 합성의 감소를 유발하고, 이로 인
하여 방사선으로 인한 디옥시리보핵산 손상이 증가함을 관찰하였
다. 이는 system xc
-의 억제가 교모세포종의 방사선 감수성을 향상
시킬 수 있음을 시사한다. 게다가 system xc
-의 억제가 방사선 유
도 세포 이동을 방해하며, 간엽성 이행 표지자들에도 영향을 주었
음을 관찰하였다. 이 모든 결과를 미루어 볼 때, 이 연구는 방사
선과 system xc
-의 병용치료가 예후가 좋지 않은 교모세포종에서의
치료 성적 향상에 기여할 수 있음을 시사한다.
핵심되는 말: System xc
-, 시스틴/글루타메이트 수송체, 방사선,
방사선감수성, 세포 이동
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